Drugs / Tinengotinib
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04705922 | Dec 2020 → Mar 2021 | — | TransThera Sciences (Nanjing), Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03654547 | Jan 2019 → Jan 2023 | triple-negative breast carcinoma | TransThera Sciences (Nanjing), Inc. | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06457919 | Jun 2024 → Jun 2027 expected | prostate cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06221774 | Feb 2024 → Aug 2025 | castration-resistant prostate carcinoma, clear cell renal carcinoma, urothelial carcinoma | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 1/2 | NCT05253053 | Apr 2022 → Aug 2024 | cholangiocarcinoma, gallbladder cancer, gastric cancer, prostate cancer +4 | TransThera Sciences (Nanjing), Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04742959 | Mar 2021 → Feb 2024 | cholangiocarcinoma, gallbladder cancer, gastric cancer, prostate cancer +5 | TransThera Sciences (Nanjing), Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07498478 | Mar 2026 → Jun 2027 expected | breast cancer | TransThera Sciences (Nanjing), Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07052253 | Jul 2025 → May 2027 expected | hepatocellular carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 2 | NCT06057571 | Nov 2023 → Jul 2025 overdue | cholangiocarcinoma | TransThera Sciences (Nanjing), Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04919642 | Dec 2021 → Feb 2024 | cholangiocarcinoma | TransThera Sciences (Nanjing), Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07328919 | Jan 2026 → Dec 2029 expected | intrahepatic cholangiocarcinoma | TransThera Sciences (Nanjing), Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05948475 | Dec 2023 → Dec 2026 expected | cholangiocarcinoma | TransThera Sciences (Nanjing), Inc. | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06370013 | — | cholangiocarcinoma | TransThera Sciences (Nanjing), Inc. | Available | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tinengotinib | “Patints orally self-administered tinengotinib 10 mg daily in 28-day cycles in 28-day treatment cycles until documented disease progression, unacceptable toxicity, or withdrawal...” PMID 41349554 ↗ Dec 202510“Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer.” PMID 36223547 ↗ Feb 2023 “Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors” NCT04742959 ↗ “TT-00420 (Tinengotinib) Capsule” NCT04705922 ↗ “Drug: TT-00420 (tinengotinib)” NCT07052253 ↗ “TT-00420 (tinengotinib)” NCT07328919 ↗ |
| Known as | TT-00420 | “This is a Phase II, open-label study to evaluate the efficacy and safety of TT00420 in patients with advanced/metastatic and surgically unresectable cholangiocarcinoma (CCA)...” NCT04919642 ↗10“Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer.” PMID 36223547 ↗ Feb 2023 “TT-00420 (Tinengotinib) Tablets Combined With Fulvestrant Injection” NCT07498478 ↗ “TT-00420 (tinengotinib)” NCT06057571 ↗ |
| Action | Inhibit | “strongly inhibited Aurora A/B, FGFR1/2/3, VEGFRs, JAK1/2, and CSF1R in biochemical assays” PMID 36223547 ↗ Feb 2023 |
| Modality | Small molecule | “Novel Spectrum-Selective Small-Molecule Kinase Inhibitor” PMID 36223547 ↗ Feb 2023 |
| Route | Oral | “Administered Orally” NCT03654547 ↗ |
| Target | CSF1R | “strongly inhibited Aurora A/B, FGFR1/2/3, VEGFRs, JAK1/2, and CSF1R in biochemical assays” PMID 36223547 ↗ Feb 2023 |
| Target | FGFR1 | “strongly inhibited Aurora A/B, FGFR1/2/3, VEGFRs, JAK1/2, and CSF1R in biochemical assays” PMID 36223547 ↗ Feb 2023 |
| Target | JAK1 | “strongly inhibited Aurora A/B, FGFR1/2/3, VEGFRs, JAK1/2, and CSF1R in biochemical assays” PMID 36223547 ↗ Feb 2023 |